Generic placeholder image

Current Enzyme Inhibition

Editor-in-Chief

ISSN (Print): 1573-4080
ISSN (Online): 1875-6662

Endothelin-Converting Enzyme Inhibitors

Author(s): Cristina Navarrete and Cleide Suguihara

Volume 2 , Issue 4 , 2006

Page: [373 - 378] Pages: 6

DOI: 10.2174/157340806778699244

Price: $65

Sekisui-XenoTech-CEI
Abstract

Endothelin-1 (ET-1) is a peptide with various biological activities, such as vasoconstriction, mitogenesis and bronchoconstriction. It has been implicated in the pathogenesis of numerous disease processes. Suppression of the production of this peptide by inhibitors of endothelin-converting enzyme-1 (ECE-1), the key enzyme in ET-1 biosynthesis, may be a therapeutic option. There are three classes of ECE-1 inhibitors: selective ECE-1 inhibitors, dual ECE-1/neutral endopeptidase (NEP) 24.11 inhibitors and triple ECE-1/NEP/angiotensin-converting enzyme inhibitors. This review will focus briefly on the endothelin system and mainly on the ECE-1 inhibitor classes, their pharmacologic effects on animal models of various diseases and published clinical studies.

Keywords: Endothelin-1, endothelin-converting enzyme, ECE-1 inhibitors


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy